Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLVS Clovis Oncology		$0.43	$0.08 ▼ $3.32	$11.60M	0.24	8.88 million shs	1.16 million shs
MGNX MacroGenics	$1.61 +1.9%	$1.48	$0.99 ▼ $5.77	$101.57M	1.59	849,087 shs	764,998 shs
MIST Milestone Pharmaceuticals	$1.56 -39.1%	$1.65	$0.63 ▼ $2.75	$83.40M	0.96	1.06 million shs	21.18 million shs
MORF Morphic	$56.99	$56.76	$19.34 ▼ $57.00	$2.85B	1.49	1.27 million shs	400 shs
STSA Satsuma Pharmaceuticals	$1.10	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	N/A

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLVS Clovis Oncology	0.00%	0.00%	0.00%	0.00%	0.00%
MGNX MacroGenics	0.00%	+11.81%	+3.87%	+24.81%	-62.30%
MIST Milestone Pharmaceuticals	0.00%	-19.34%	-7.14%	+102.26%	+7.59%
MORF Morphic	0.00%	0.00%	0.00%	0.00%	+2.24%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLVS Clovis Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	4.2605 of 5 stars	3.2	4.0	0.0	4.4	1.5	2.5	0.6
MIST Milestone Pharmaceuticals	2.7793 of 5 stars	3.2	4.0	0.0	0.0	3.0	2.5	0.0
MORF Morphic	0.9963 of 5 stars	1.0	0.0	0.0	4.8	0.0	3.3	0.0
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLVS Clovis Oncology	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.40	Hold	$5.71	254.92% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	348.72% Upside
MORF Morphic	2.00	Hold	$57.00	0.02% Upside
STSA Satsuma Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MGNX, MORF, CLVS, MIST, and STSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLVS Clovis Oncology	$148.76M	0.00	N/A	N/A	($2.15) per share	0.00
MGNX MacroGenics	$149.96M	0.68	N/A	N/A	$1.85 per share	0.87
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
MORF Morphic	$520K	5,490.11	N/A	N/A	$12.31 per share	4.63
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLVS Clovis Oncology	-$264.52M	-$1.83	N/A	N/A	N/A	-189.37%	N/A	-57.78%	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)
MORF Morphic	-$152.10M	-$3.50	N/A	N/A	N/A	N/A	-26.62%	-25.74%	N/A
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A

Latest MGNX, MORF, CLVS, MIST, and STSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLVS Clovis Oncology	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MORF Morphic	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLVS Clovis Oncology	N/A	0.14	0.12
MGNX MacroGenics	N/A	3.28	3.11
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
MORF Morphic	N/A	24.13	24.13
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLVS Clovis Oncology	24.53%
MGNX MacroGenics	96.89%
MIST Milestone Pharmaceuticals	86.18%
MORF Morphic	94.25%
STSA Satsuma Pharmaceuticals	93.26%

Insider Ownership

Company	Insider Ownership
CLVS Clovis Oncology	4.40%
MGNX MacroGenics	13.00%
MIST Milestone Pharmaceuticals	19.50%
MORF Morphic	25.60%
STSA Satsuma Pharmaceuticals	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLVS Clovis Oncology	N/A	144.96 million	138.58 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
MORF Morphic	100	50.09 million	37.27 million	Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable

MGNX, MORF, CLVS, MIST, and STSA Headlines

Recent News About These Companies

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

June 19, 2025 | prnewswire.com

Durham-based Satsuma wins FDA approval for migraine treatment

May 21, 2025 | ncbiotech.orgN

Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight

May 16, 2025 | theglobeandmail.com

FDA approves Atzumi for acute migraine treatment in adults

May 6, 2025 | healio.comH

FDA Okays Dihydroergotamine Nasal Spray for Acute Migraine

May 5, 2025 | medscape.comM

Nasal Powder for Acute Migraine Gets FDA Nod

May 2, 2025 | msn.com

FDA clears Satsuma’s Atzumi for migraine

May 2, 2025 | bioworld.comB

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi

May 1, 2025 | contractpharma.comC

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

April 30, 2025 | prnewswire.com

Satsuma Pharmaceuticals Inc (STSA)

April 10, 2025 | uk.investing.com

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

November 26, 2024 | prnewswire.com

SNBL’s Subsidiary Resubmits Migraine Drug Application

October 31, 2024 | markets.businessinsider.com

Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura

October 30, 2024 | prnewswire.com

Aprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News Summary

October 10, 2024 | benzinga.com

Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs

October 8, 2024 | prnewswire.com

Satsuma, AL Weather Conditions

August 21, 2024 | wunderground.comW

Satsuma pulped as acute migraine drug flunks phase 3 trial

August 9, 2024 | pharmaphorum.comP

Satsuma, FL Weather Conditions

July 29, 2024 | wunderground.comW

Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting

June 13, 2024 | prnewswire.com

With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray

January 18, 2024 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, MORF, CLVS, MIST, and STSA Company Descriptions

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

MacroGenics NASDAQ:MGNX

$1.61 +0.03 (+1.90%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.61 0.00 (0.00%)

As of 07/11/2025 07:28 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Milestone Pharmaceuticals NASDAQ:MIST

$1.56 -1.00 (-39.06%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.05 (+3.21%)

As of 07/11/2025 07:59 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time